International Review of Neurobiology, 129 , 85110
Pharmacological Reports 71, 338346.CrossRefGoogle Scholar Dichter, GS, Damiano, CA and Allen, JA (2012) Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings
A.IkonomopoulosI.BannisterA
Some studies show these medications reduce the rates of complications like chronic kidney disease or nephropathy
A 20% relative risk reduction in MACE, including myocardial infarction, stroke, and cardiovascular death and a 30% relative risk reduction in hospitalizations for HF ( The VERTIS trial, involving 8246 patients with T2DM, compared ertugliflozin 5 mg or 15 mg daily to placebo for 3.5 years
This is promising mechanistic evidencenot a clinical cure